Back to Cognition
Cognition

L-TyrosineEvidence & Dosage

Dopamine precursor, stress performance and sleep deprivation

Studies last updated

Evidence at a glance

Total studies
810
With abstract
45
Meta / Systematic / RCT
107
Highly cited
13
Publication years
2005–2026

L-Tyrosine in the context of Cognition

This topic is part of our "Cognition" world. There you'll find methodology, evidence and the highest-impact levers — plus the order in which they sensibly build on each other.

Go to Cognition

Top studies on L-Tyrosine

Ranked by influential-citation count and publication year.

  1. L-tyrosine alleviates autism-like behavior in mice by remodeling the gut microbiota.

    202544 influential citations

    Autism spectrum disorder (ASD) is characterized by impaired social interaction and repetitive stereotyped behavior, and effective interventions for the core autistic symptoms are currently limited. This study examines the protective role…

  2. Locoregional Therapies for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

    JAMA Netw Open2024n=11,576Meta-Analysis43 influential citations

    <h4>Importance</h4>Several locoregional therapies (LRTs) for nonmetastatic hepatocellular carcinoma (HCC) are available; however, a global comparison of the relative efficacy of each is needed.<h4>Objective</h4>To conduct a systematic…

    Finding: Adjuvant treatment after surgery was associated with improved progression-free survival and overall survival compared with surgery alone.

  3. Fungal infection in patients treated with Bruton tyrosine kinase inhibitor-from epidemiology to clinical outcome: a systematic review.

    Clin Microbiol Infect2025n=25,426Systematic Review37 influential citations

    <h4>Background</h4>The Bruton tyrosine kinase inhibitor (BTKi) has emerged as a key treatment for B-cell lymphomas. Despite its efficacy in the treatment of malignancies, numerous cases of invasive fungal infections (IFI) have been…

  4. Immunotherapy improved the efficacy of TACE or TACE plus MTTs in HCC patients: A meta-analysis.

    Int Immunopharmacol2025n=258Meta-Analysis32 influential citations

    <h4>Background</h4>Although several studies have compared the efficacy and safety of transarterial chemoembolization (TACE) without immune checkpoint inhibitors (ICIs) and TACE with ICIs, there is still a lack of…

  5. Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis.

    Crit Rev Oncol Hematol2025n=784Meta-Analysis23 influential citations

    <h4>Background</h4>Primary central nervous system lymphoma (CNSL) is a rare, aggressive non-Hodgkin lymphoma confined to the CNS. Although radiation and chemotherapy, particularly high-dose methotrexate (HD-MTX), are effective treatments,…

    Finding: The review found no significant differences in the efficacy of ibrutinib between CNSL subtypes.

  6. Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials.

    Int Immunopharmacol2025n=134Meta-Analysis22 influential citations

    <h4>Background</h4>Soft tissue sarcomas (STS) are a heterogeneous group of tumors with diverse clinical and molecular characteristics, characterized by limited treatment options and poor prognosis. Immune checkpoint inhibitors (ICIs) have…

    Finding: The overall objective response rate for immune checkpoint inhibitors in soft tissue sarcoma was 16%.

  7. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.

    BMC Cancer2024n=8,359Meta-Analysis14 influential citations

    <h4>Background</h4>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and EGFR-TKI combination treatments have become the standard first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC) patients.…

    Finding: In untreated advanced EGFR-mutated NSCLC, osimertinib plus chemotherapy and lazertinib plus amivantamab showed the highest efficacy in improving progression-free survival.

  8. The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

    Clin Genitourin Cancer2024n=16,072Meta-Analysis11 influential citations

    Although immune checkpoint inhibitors (ICI) and/or tyrosine kinase inhibitors (TKI) are the standard treatment of advanced unresectable or metastatic renal cell carcinoma (RCC), the impact of concomitant medications remains unclear. We…

  9. Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results.

    Expert Opin Emerg Drugs2024Systematic Review6 influential citations

    <h4>Introduction</h4>Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a major cause of cancer-related morbidity and mortality. Limited treatment options for advanced stages highlight the need for effective…

  10. The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis.

    BMC Pharmacol Toxicol2024n=715Meta-Analysis5 influential citations

    <h4>Background</h4>The belzutifan is a hypoxia inducible factor-2 alpha (HIF-2α) inhibitor for the treatment of advanced or metastatic clear cell renal cell carcinoma (mccRCC) and has exhibited good safety and efficacy in clinical trials.…

Frequently asked

What dosage was studied?
• Small-molecule protein kinase inhibitors (PKIs) as targeted therapy • L-tyrosine supplementation • Locoregional therapies (surgery with or without adjuvant therapy, RFA, MWA, RT, HAIC, TAE, TACE, TARE) (Varied by included trials; examples reported include MWA 4- to 6-minute application at 140 W and RT 66 GyE in 10 fractions)
Are there safety considerations for L-Tyrosine?
• No adverse events summary reported in the excerpt. • IFI occurred with first-, second-, and third-generation BTKi. • Survival improved when BTKi was discontinued during infection. • Adding ICIs to TACE + TKIs did not increase adverse events.

More topics in Cognition

Bacopa Monnieri

Memory, Bacosides, Long-term Effect and Tolerance

Acetyl-L-Carnitine (ALCAR)

Mitochondria, neuroprotection, and energy metabolism.

Acetylcholine

Memory, attention, REM sleep, choline sources.

Active Recall

Retrieval over rereading — a scientifically superior way to learn.

Alpha-GPC

Choline source for acetylcholine and cognitive performance

Binaural Beats

Auditory frequency stimulation — mixed evidence.

Blood-Brain Barrier

Selective permeability, substance passage, inflammation-driven leakiness.

Brain Fog

Multifactorial: sleep, blood sugar, inflammation, thyroid, long COVID.

Caffeine

Adenosine-receptor antagonist, tolerance, timing, half-life, genetics.

Citicoline (CDP-Choline)

Phospholipid synthesis, ADHD, and neurological applications.

Creatine

More than just sport: memory, sleep deprivation, vegan deficits.

Deep Work

Focused, distraction-free work as a trainable skill.

Dopamine

Motivation, reward, movement, learning — the brain's core reward chemistry.

Dopamine Detox

A popular trend without strong scientific backing — what still holds up.

Exercise & Learning

BDNF, the hippocampus, cognitive reserve — exercise makes you sharper.

Flow State

Optimal state of consciousness during full immersion — conditions and triggers.

Ginkgo Biloba

Microcirculation, memory, and dementia interactions.

Glucose vs Ketones

The brain's fuel sources, ketogenic adaptation, cognitive effects.

Histamine

Wakefulness, allergy, histamine intolerance and brain fog.

L-Theanine

Alpha waves, relaxation without sedation, caffeine synergy.

Related topics from other worlds

Methods

Paleo Diet

Stone-age inspired — what the evidence actually shows.

Methods

Salt & Sodium

Individual salt sensitivity, blood pressure, electrolyte balance.

Methods

Sugar

Fructose vs. glucose, added sugar, the metabolic fallout.

Longevity

AMPK Activators

Berberine, alpha‑lipoic acid, energetic stress, and glucose modulation.

Longevity

Cellular Senescence

"Zombie cells," SASP, senolytic approaches.

Longevity

Genetic Tests

Variants, pharmacogenomics, limitations — methylation, MTHFR myths.